The Roles of PI3K/AKT/mTOR and MAPK/ERK Signaling Pathways in Human Pheochromocytomas

Juan Du,1 Anli Tong,1 Fen Wang,1 Yunying Cui,1 Chunyan Li,1 Yushi Zhang,2 and Zhaoli Yan3

1Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuaifuyuan No. 1, Dongcheng District, Beijing 100730, China
2Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
3Department of Endocrinology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China

Correspondence should be addressed to Anli Tong; tonganli@hotmail.com

Received 19 June 2016; Revised 2 October 2016; Accepted 27 October 2016

Academic Editor: Thomas J. Fahey

Copyright © 2016 Juan Du et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. The roles of PI3K/AKT/mTOR and MAPK/ERK pathways involved in the pathogenesis of pheochromocytoma and paraganglioma (PPGL) were demonstrated mostly by in vitro studies with rat or mouse cells and were mainly studied at transcriptional level. This study aimed to investigate the effect of these pathways on the proliferation of human PPGL cells and the activation of these pathways in PPGL.

Methods. Human PPGL cells were treated with sunitinib and inhibitors of PI3K (LY294002), MEK1/2 (U0126), and mTORC1/2 (AZD8055). Cell proliferation was detected by MTT assay. Protein phosphorylation was detected by Western blotting.

Results. In most PPGLs, AKT, ERK1/2, and mTOR were activated. LY294002 (10 𝜇M), U0126 (10 𝜇M), AZD8055 (1 𝜇M), and sunitinib (1 𝜇M) inhibited PPGL cell proliferation in ten primary cultures of tissues, including four from patients with gene mutations. MEK1/2 inhibitor decreased mTOR phosphorylation. Inhibition of mTOR reduced phosphorylation of AKT and ERK1/2. Sunitinib inhibited phospho-ERK1/2 and phospho-mTOR.

Conclusion. Our study suggested that PI3K/AKT/mTOR and MAPK/ERK signaling pathways play vital roles in human PPGL and are activated in most PPGLs. Inhibiting multiple pathways might be a novel therapeutic approach for PPGLs.

1. Introduction

Pheochromocytomas and paragangliomas (PPGLs) are neuroendocrine tumors arising from adrenomedullary chromaffin cells and extra-adrenal chromaffin cells of the sympathetic or parasympathetic ganglia. The tumors are associated with life-threatening complications due to their ability to release catecholamines—norepinephrine, epinephrine, and dopamine [1]. Once the diagnosis is established, the therapy of choice is radical resection.

Most PPGLs are benign and surgically curable, but when they are malignant, recurrent, or irremovable few effective therapies are available [2]. Intensive studies on PPGL tumorigenesis have led to the development of targeting drugs designed to improve the outcome of the tumors. PPGLs are generally divided into two major clusters [3–9]. Cluster I includes the tumors with von Hippel-Lindau (VHL) gene and the subunits of the succinate dehydrogenase (SDHx) mutation that lead to dysregulation of Krebs cycle and activation of hypoxia signaling pathway [10]. Cluster 2 involves the tumors with the mutation of rearranged during transfection (RET), neurofibromin 1 (NF1), kinesin family member 1B (KIF1Bb), transmembrane protein 127 (TMEM127), and MYC-associated factor X (MAX), which are associated with abnormal activation of phosphatidylinositol 3′ kinase (PI3K)/protein kinase B (AKT), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), and mammalian target of rapamycin C1 (mTORC1)/p70S6K [11].

Recent studies on the prosurvival molecular pathways such as PI3K/AKT/mTOR and MAPK/ERK revealed that they play important roles in tumorigenesis of a wide array
of tumors, including PPGLs [12]. The role of MAPK pathway in the pathogenesis of PPGL has been documented by a number of studies [13, 14]. Upregulated mRNA expression involving MAPK signaling pathway has been observed in the RET/NF1/TMEM127-related PPGL tissues [15]. In addition, elevated phosphorylation of AKT in sporadic PPGLs was found by using Western blotting and immunohistochemical detection [16]. Moreover, inhibition of PI3K/AKT pathway could effectively suppress proliferation of rat pheochromocytoma PC12 cells in vitro [17]. mTOR is a serine/threonine kinase involved in the regulation of cell growth and proliferation and consists of two separate protein kinase complexes, mTORC1 and mTORC2 [18]. The dysregulation of the mTOR signaling pathway was found to be associated with human tumors, including PPGLs [19]. Recently, Giubellino et al. found that the expression of mTOR (mTORC1 and mTORC2) mRNA was higher in PPGLs with SDHB and VHL mutations than in normal adrenal medulla [20]. AZD8055, a newly identified inhibitor targeting both mTORC1 and mTORC2, was found to be able to significantly inhibit both proliferation and migration of mouse PPGL cells in vitro, suggesting that targeted inhibition of mTOR promises to be a novel therapeutic alternative for PPGLs [20].

Mounting evidence has shown that the aforementioned pathways play significant roles in the pathogenesis of PPGLs, demonstrated mostly by in vitro studies with rat or mouse cells. Moreover, signaling pathways involving PPGLs were mainly observed at transcriptional level and little is known about the activation and roles of these pathways in human PPGLs. In addition, no studies have been conducted concerning the cross talk between these two vital cellular pathways, PI3K/AKT/mTOR and MAPK/ERK, in PPGLs. In this study, we examined the effect of PI3K/AKT/mTOR and MAPK/ERK pathways on the growth of human PPGL cells and their interactions. We also observed the phosphorylation level of key proteins in these pathways in PPGLs with different gene mutations.

2. Materials and Methods

2.1. Reagents. LY294002 (PI3K inhibitor) and U0126 (MEK1/2 inhibitor) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) and bicinchoninic acid (BCA) kit were purchased from Sigma-Aldrich (St. Louis, MO, USA). AZD8055 (mTORC1/2 inhibitor) and sunitinib (a multitargeted receptor tyrosine kinase inhibitor) were procured from Selleck (Houston, Texas, USA). The PPGL cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 15% fetal bovine serum (FBS) and 50 units/mL penicillin/50 mg/mL streptomycin ( Gibco-Life Technologies, Grand Island, NY, USA). Antibodies against phospho-AKT (Ser473), phospho-p44/42MAPK (ERK1/2) (Thr202/Tyr204), and phospho-mTOR (Ser2448) were obtained from Cell Signaling Technology (Beverly, MA, USA). β-Actin antibody was from Sigma-Aldrich (St. Louis, MO, USA). Secondary antibodies were horseradish peroxidase-conjugated goat anti-mouse IgG (MultiSciences, Beijing, China) used for p-AKT, p-ERK1/2, and β-actin and goat anti-rabbit IgG (MultiSciences, Beijing, China) for p-mTOR. Protease inhibitor cocktail was from Roche (Indianapolis, IN, USA). Tissue protein extraction reagent was purchased from Applygen Technologies (Beijing, China).

2.2. Human Tumor Samples. Tumor samples were collected during surgical excision. Fresh tumor tissues were immediately treated for cell culture or frozen for Western blot study. PPGLs were histopathologically identified. All patients were screened for germline mutations of VHL, RET, SDHB, SDHC, and SDHD genes. In addition, nine nonmetastatic PPGLs (3 with RET mutation, 3 with VHL mutation, and 3 with SDHB mutation) were harvested for Western blotting. Clinical data of the patients are presented in Table I. Informed consent was obtained from all subjects and the study was approved by the PUMCH Ethics Committee for Human Research with an IRB approval number of S-K084.

2.3. Cell Culture. Human PPGL cells were primarily cultured as previously described [21]. In brief, human PPLG cells were taken by sequential collagenase (type I) digestion from PPGL tissues and incubated in DMEM supplemented with 15% FBS and antibiotics at 37°C in 5% CO₂ atmosphere. Cells were allowed to adhere and grew fully under standard conditions.

2.4. Drug Treatment and Protein Extraction. Human PPGL cells were plated into 6-well plates at a density of 10⁵ cells/well and were allowed to grow until they were 80% confluent. Then, cells were treated to determine the optimal stimulation time and the optimal concentration of the inhibitors as follows: (1) after serum starvation for 6 hours, cells were treated with the serum (the final concentration of serum in medium was 15%) for different incubation periods (5, 15, 30, and 60 min). (2) Serum-starved cells were pretreated with increasing concentrations of selective antagonists, including LY294002 (0.1, 1, 5, and 10 μM), U0126 (0.1, 1, 5, and 10 μM), AZD8055 (0.01, 0.1, 1, and 5 μM), and sunitinib (0.01, 0.1, and 1 μM) for 30 min, and stimulated with the serum (the same final concentration as mentioned previously) for 5 min. Finally, cells were harvested and phosphorylation of AKT, ERK1/2, and mTOR was determined by Western blotting. Because serum-stimulated cells had a conspicuous positive expression of p-AKT, p-ERK1/2, and p-mTOR, cells treated with the serum could naturally be taken as a positive control. Upon the determination of the optimal stimulation time and concentration of the antagonists, the cells were pretreated with LY294002 (10 μM), U0126 (10 μM), AZD8055 (1 μM), sunitinib (1 μM), or vehicle for 30 min and incubated with the serum for another 5 min. Cells were then collected and washed twice with ice-cold PBS. The lysates were prepared with cell lysis buffer supplemented with complete protease inhibitor cocktail. Afterwards, the lysates were centrifuged at 10000×g at 4°C for 10 min and the supernatants were quantitatively detected for total protein by using the BCA assay. Frozen tissues were homogenized on ice in a tissue protein extraction reagent according to the manufacturer's protocol. The soluble protein concentrations were determined before loading.
Table 1: Patients’ information.

| Patient | Gender | Age at diagnosis (years) | Location | Genetic background | Tumor size (cm) | Urinary norepinephrine (μg/24h) | Urinary epinephrine (μg/24h) | Urinary dopamine (μg/24h) |
|---------|--------|--------------------------|----------|-------------------|----------------|-------------------------------|----------------------------|--------------------------|
| N1      | F      | 72                       | Adrenal  | N                 | 3.0            | 22.4                         | 3.7                        | 156.6                    |
| N2      | F      | 57                       | Adrenal  | N                 | 4.0            | 19.3                         | 1.9                        | 181.3                    |
| N3      | F      | 40                       | Adrenal  | N                 | 4.7            | 16.9                         | 1.5                        | 67.9                     |
| N4      | M      | 59                       | Adrenal  | N                 | 6.3            | 100.9                        | 2.8                        | 140.1                    |
| N5      | F      | 26                       | Adrenal  | N                 | 4.0            | 20.4                         | 2.3                        | 135.7                    |
| N6      | M      | 40                       | Adrenal  | N                 | 5.0            | 177.1                        | 1.1                        | 256.6                    |
| D1      | F      | 47                       | Adrenal  | SDHD              | 8.0            | 215.0                        | 2.8                        | 311.1                    |
| B1      | M      | 26                       | Retroperitoneal | SDHB        | 5.0            | 138.9                        | 2.3                        | 1046.5                   |
| B2      | F      | 62                       | Adrenal  | SDHB              | 3.7            | 15.4                         | 1.9                        | 177.4                    |
| B3      | F      | 48                       | Retroperitoneal | SDHB        | 9.0            | 121.4                        | 1.8                        | 147.1                    |
| V1      | M      | 21                       | Adrenal  | VHL               | 7.5            | 937.5                        | 2.3                        | 127.3                    |
| V2      | F      | 34                       | Adrenal and retroperitoneal | VHL   | 4.5 (adrenal)/4.0 (retroperitoneal) | 239.2                        | 13.3                        | 153.8                    |
| V3      | M      | 8                        | Adrenal  | VHL               | 4.0            | 214.1                        | 4.6                        | 98.3                     |
| R1      | F      | 33                       | Adrenal  | RET               | 3.7            | 13.9                         | 2.7                        | 237.6                    |
| R2      | F      | 30                       | Adrenal  | RET               | 5.0            | 21.2                         | 5.3                        | 456.2                    |
| R3      | M      | 49                       | Adrenal  | RET               | 2.4            | 20.8                         | 3.5                        | 326.3                    |
| R4      | F      | 27                       | Adrenal  | RET               | 7.3            | 20.5                         | 3.0                        | 163.2                    |
| R5      | F      | 45                       | Adrenal  | RET               | 6.9            | 315.3                        | 2.6                        | 268.8                    |

N: PPGL without gene mutation of SDHB, SDHC, SDHD, VHL, and RET; M: male; F: female. Reference range: urinary norepinephrine 16.7–40.7 μg/24h; urinary epinephrine 1.7–6.4 μg/24h; urinary dopamine 120.9–330.6 μg/24h.

2.5. Western Blot Analysis. Western blotting was performed as described before with minor modifications [22]. Proteins were separated on 8%–12% SDS-PAGE, transferred to polyvinylidene difluoride membrane, and blocked with milk. Membranes were incubated with primary antibodies for p-AKT, p-ERK1/2, p-mTOR, and β-actin overnight at 4°C and then with horseradish peroxidase-conjugated secondary antibodies at room temperature for 1 hour. The bands were visualized on an enhanced chemiluminescence (ECL) detection system (GE Healthcare, Little Chalfont, UK).

2.6. Cell Proliferation Assay. Cells were plated into 96-well plates at a density of 4 × 10⁴ cells/well in a final volume of 200 μL and cultured for 4 days. Afterwards, cells were incubated in fresh 15% FBS DMEM with or without LY294002 (10 μM), U0126 (10 μM), AZD8055 (1 μM), and sunitinib (1 μM) for 48 hours. Culture medium was removed and MTT solution was added to the plates. Cells were incubated at 37°C for 1 hour. Then, the medium was removed and DMSO was added to dissolve the purple formazan crystals for three hours. Finally, the plates were read on a microplate reader (Bio-TEK Instruments, Vermont, USA) at 490 nm with a reference filter at 630 nm. For each PPGL sample (n = 10), 5 sets (or groups) of wells were set up, each set having 4 wells.

2.7. Statistical Analysis. Data were statistically analyzed by employing the SPSS 14.0 software package. The data of Western blotting were expressed as means ± standard deviation, and the significance of differences was evaluated by paired samples t-test. Meanwhile, the data from cell proliferation assay were presented as means ± standard deviation, and significance of differences was assessed by using independent samples t-test. P < 0.05 was considered to be statistically significant.

3. Results

3.1. Phosphorylation of AKT, ERK1/2, and mTOR in PPGL Tissues. Whether PI3K/AKT/mTOR and MAPK/ERK pathways are activated in PPGLs remains unknown. Therefore, we examined the phosphorylation of AKT, ERK1/2, and mTOR in PPGL tumor samples. First, phosphorylation was detected in 6 samples used for in vitro experiments, and the result revealed that p-AKT, p-ERK1/2, and p-mTOR varied greatly with different human PPGL tissues (Figure 1(a)). To clarify whether such variation was dictated by genetic background of the tumors, 9 PPGLs with different gene mutations were analyzed. Figure 1(b) showed that ERK1/2 was activated in all PPGLs and AKT and mTOR were activated in most of the tumors. Phosphorylation of AKT and ERK1/2 appeared to be more pronounced in SDHB-related PPGLs than in VHL-related PPGLs. mTOR phosphorylation was detected in all the three SDHB-related PPGLs, while it was detected only in one VHL-related tumor. RET-related PPGLs showed conspicuous activation of AKT and ERK1/2, and mTOR activation was detected in two of the three RET-related tumors.

3.2. Effect of Pathway Inhibitors on Phosphorylation of AKT, ERK1/2, and mTOR. Figures 2(a)–2(d) show that LY294002,
Figure 1: Phosphorylation of AKT, ERK1/2, and mTOR in PPGL tissues. (a) Phosphorylation of AKT, ERK1/2, and mTOR in 6 PPGLs used in _in vitro_ experiments. (b) Phosphorylation of AKT, ERK1/2, and mTOR in 9 PPGLs from patients with different gene mutations. β-Actin was used as a loading control. N: PPGL without gene mutation of SDHB, SDHC, SDHD, VHL, and RET; B: PPGL with SDHB mutation; D: PPGL with SDHD mutation; V: PPGL with VHL mutation; R: PPGL with RET mutation.

Figure 2: Effects of pathway inhibitors on phosphorylation of AKT, ERK1/2, and mTOR in human PPGL cells. (a–d) Dose-dependent inhibition of p-AKT (a), p-ERK1/2 (b), and p-mTOR (c, d) by pathway inhibitors (LY294002 (a), U0126 (b), AZD8055 (c), and sunitinib (d)). (e) Time course of phosphorylation of AKT, ERK1/2, and mTOR induced by the serum. (f) Effects of LY294002 (10 μM), U0126 (10 μM), AZD8055 (1 μM), and sunitinib (1 μM) on the phosphorylation of AKT, ERK1/2, and mTOR in human PPGL cells. β-Actin was used as a loading control. Because serum-stimulated cells had a conspicuous positive expression of p-AKT, p-ERK1/2, and p-mTOR, cells treated with the serum could naturally be taken as a positive control. The experiment was repeated three times. (g, h, i) The histograms represent the densitometric results of the phosphorylation from three independent experiments. ERK1/2, AKT, and mTOR phosphorylation in FBS group was taken as 100%. * _P_ < 0.05 versus FBS group; ** _P_ < 0.01 versus FBS group.
Figure 3: Effect of pathway inhibitors on cell proliferation in human PPGL cells. Experiments were performed in four independent wells for each group (n = 4) and repeated in ten PPGLs (N = 10). The results were represented in the scatter diagram (a) and column chart (b). **P < 0.01 versus control group; # P < 0.05 versus LY294002 group; % P < 0.05 versus U0126 group. N: PPGL without gene mutation of SDHB, SDHC, SDHD, VHL, and RET; B: PPGL with SDHB mutation; D: PPGL with SDHD mutation; R: PPGL with RET mutation.

U0126, AZD8055, and sunitinib dose-dependently inhibited AKT, ERK1/2, or mTOR phosphorylation at the optimal concentration of 10 μM (for LY294002 and U0126) and 0.1–1 μM (for AZD8055 and sunitinib). Stimulation of the cells with serum for different periods of time caused time-dependent phosphorylation of ERK1/2 and AKT with the maximum effect occurring at 5 min. Additionally, mTOR was highly activated 5 min after the stimulation (Figure 2(e)). Treatment with LY294002 (10 μM) reduced only AKT phosphorylation. U0126 (10 μM) inhibited ERK1/2 phosphorylation and downregulated the activation of mTOR. AZD8055 (1 μM) significantly inhibited the activation of AKT, ERK1/2, and mTOR. Treatment with sunitinib (1 μM) in PPGL cells dramatically downregulated both ERK1/2 and mTOR phosphorylation. The findings suggested that there was a cross talk between MAPK/ERK and PI3K/AKT/mTOR signaling pathways (Figures 2(f)–2(i)).

3.3. Effect of Pathway Inhibitors on the Proliferation of Human PPGL Cells. To determine the roles of the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in the survival of human PPGL cells, human PPGL cells were, respectively, treated with corresponding inhibitors of the pathways. As shown in Figure 3, LY294002 (10 μM), U0126 (10 μM), AZD8055 (1 μM), and sunitinib (1 μM) inhibited PPGL cell proliferation in ten primary cultures of tissues from different patients, including four patients with gene mutations (2 with RET mutation, 1 with SDHD mutation, and 1 with SDHB mutation) (Figures 3(a) and 3(b)). Only in two unrelated cultures did the cells fail to respond to the treatment of LY294002. Cells in another three unrelated cultures did not respond to U0126 (Figure 3(a)). mTORC1/2 inhibitors and sunitinib exerted stronger inhibiting effect on cell growth compared to PI3K inhibitor and MEK1/2 inhibitor (Figure 3(b)).

4. Discussion

Understanding the changes in signaling pathways involved in PPGLs can help us find new targets for tumor treatment. In this study, we looked into the role of the signaling pathways in the pathogenesis by blocking related pathways with their respective inhibitors, with an attempt to understand the impact of these pathways on the survival of tumor cells.

PC12 cells, originating from rat pheochromocytoma, have been widely employed as a model for the study of pathogenesis of PPGLs. On the other hand, some researchers also used a newly established mouse pheochromocytoma cell line from heterozygous NF1 gene knockout mice [23]. Although they are all of pheochromocytoma origin, they might not necessarily undergo the molecular and functional changes that true human catecholamine-producing tumors go through in vivo. In our study, we used the primary culture of human PPGL cells and presumably the conditions could better mimic the environment of human PPGLs.

This study showed that separately blocking PI3K/AKT/mTOR and MAPK/ERK signaling pathways was able to inhibit the proliferation of human PPGL cells from patients with different gene backgrounds. Furthermore, Western blot studies showed that PI3K/AKT/mTOR and MAPK/ERK signaling pathways were activated when PPGL cells were treated with serum, suggesting that these signaling pathways are functionally correlated in tumorigenesis. To our knowledge, this is the first experimental evidence showing a strong correlation between the tumorigenicity of pheochromocytoma
cells and the activity of these signaling molecules in a human primary cell culture model.

Extensive cross talk between PI3K/AKT/mTOR and MAPK/ERK pathways has been previously documented. These two signaling pathways have been proved to be implicated in the cross talk between insulin and Ang II systems. ERK phosphorylation stimulated by Ang II inhibited insulin-induced activation of the IRS-1/PI3K/AKT pathway [24]. Our study demonstrated that inhibition of MEK resulted in decreased phosphorylation of mTOR. Also, specific inhibition of mTOR activation by AZD8055 reduced phosphorylation of both AKT and ERK. These results supported the notion that PI3K/AKT/mTOR and MAPK/ERK signaling pathways are not independent but interactive. Compensatory activation of PI3K/AKT and MAPK signaling pathways has been demonstrated previously [25]. In human neuroendocrine tumor cell lines, blockage of Raf inhibited ERK1/2 phosphorylation but strongly induced AKT phosphorylation, suggesting that there exists a compensatory feedback loop between these two pathways [26]. Conversely, the upregulation of PI3K signaling pathway induced by epidermal growth factor caused MEK inhibition [27]. However, this compensatory feedback loop was not observed in our study. Moreover, it is well documented that inhibition of both MEK/ERK and mTOR substantially enhanced their antitumor effects on prostate cancer both in vitro and in vivo [28]. A recent study demonstrated that treatment with NVP-BEZ23 (PI3K/mTORC1/2 inhibitor) in combination with lovastatin (ERK1/2 inhibitor) exerted a significant additive antitumor viability in mouse PPGL cell lines [29]. Given these findings, a question will present itself as to whether concurrent MAPK and mTOR inhibition may result in substantially enhanced antitumor effects on human PPLG cells.

mTOR serves as a connector between PI3K/AKT signaling and critical downstream pathways and is a master regulator of cell proliferation and survival [30]. Activated AKT promotes mTORC1 signaling pathway by decreasing TSC1/2 inhibition [19], while mTORC1 inhibition alone leads to compensatory activation of AKT signaling pathway mediated by mTORC2 [31]. In the present study, mTORC1/2-mediated inhibition of human PPGL cell proliferation was the strongest as compared to PI3K- and MAPK-mediated inhibition, indicating that mTOR might be a major regulator of cell proliferation. We also found that inhibition of both mTORC1 and mTORC2 strongly downregulated AKT activation, and the finding was consistent with the result observed in rat pheochromocytoma PC12 cell tumor model, which showed that PP242, dual mTOR complex 1 and 2 inhibitor, but not rapamycin, dramatically inhibited tumor growth, suggesting that mTORC2 inhibition plays an important role and could disturb the mTORC1-dependent negative feedback loops [32]. Therefore, inhibition of both mTORC1 and mTORC2 might be a novel therapeutic approach for PPGGLs and might overcome the problems associated with the use of mTORC1 inhibitor alone. A recent study, by separately transfecting with mTORC1, mTORC2, and mTORC1/2 small interfering RNA, found that targeted inhibition of mTORC-2 or mTORC2, but not mTORC1, could effectively prevent proliferation, migration, and invasion and promote apoptosis of PC12 cell line [33]. These data suggest that targeting mTORC2 might be a novel alternative for the treatment of PPGGLs. Nonetheless, mTORC2-specific inhibitors are not available and more studies are warranted to confirm the speculation.

Sunitinib is an small-molecule multitargeting inhibitor of receptor tyrosine kinase (RTK), with antiangiogenic and antitumor activity that primarily targets vascular endothelial growth factor receptors (VEGFRs) [34, 35]. It has been found that PI3K/AKT, protein kinase C (PKC) family, and MAPK/Ras signaling cascades played important roles in RTK-activation-related cancer development [36]. Our results revealed that sunitinib was able to block the proliferation of human PPGL cells by inhibiting p-mTOR in the PI3K/AKT/mTOR signaling pathway and p-ERK in the MAPK signal pathway. These findings suggest that inhibition of multiple cell signaling pathways contributes to the antitumor effect of sunitinib. Saito et al. demonstrated that sunitinib directly inhibited mTOR-C1 signaling pathway, which in turn led to apoptosis of PC12 cells [37]. Denome et al. exhibited a dual inhibitory effect of sunitinib on both angiogenesis and tumor cell viability in a pheochromocytoma xenograft model [38]. Moreover, it has been shown that the suppression of mTOR-C1 signaling pathway enhanced sunitinib-induced autophagy in rat pheochromocytoma PC12 cells [39]. Clinical case reports demonstrated that sunitinib appeared to be effective for the treatment of malignant PPGGLs [40]. A study reported that about half of seventeen patients with progressive metastatic PPGGLs treated with sunitinib showed favorable clinical results [41]. These findings, together with our present results, suggest that sunitinib promises to be an effective agent that directly, though partially, inhibits PI3K/AKT/mTOR and MAPK pathways.

In this study, we also examined the activation of PI3K/AKT/mTOR and MAPK signaling pathways in PPGGLs. We found that AKT, ERK, and mTOR were activated in most PPGGLs. Furthermore, their activation appeared to be more pronounced in SDHB-related PPGGLs than in VHL-related PPGGLs but larger sample studies are needed to further confirm the result. It has been reported that SDHB-mutated tumors possessed high metastatic potential [42]. Therefore, the difference in PI3K/AKT and MAPK/ERK signaling pathways observed in this study might be associated with the malignant nature of SDHB-associated PPGGLs. In this study, we observed a wide variation in activation states in VHL- and RET-associated PPGGLs, which has yet to be explained in further studies.

As far as we know, this is the first study exploring the molecular pathways in primary human PPGGL cells. However, the study has some limitations. Firstly, up to 19 possible susceptibility genes are associated with the pathogenesis of PPGGLs and not all susceptibility genes were detected in our series. Secondly, the sample size of our study was relatively small. Because the sample size of the tumors with gene mutations is not large enough to make a comparison among genotypes, we could not tell exactly whether any of the 4 inhibitors work better in any of the genotypes. Thirdly, we were not able to perform apoptosis and invasion/migration experiments in this study as we did not have enough cells to conduct these assays. Finally, we currently do not have
any data concerning the mRNA transcription levels for these pathways.

In conclusion, PI3K/AKT/mTOR and MAPK/ERK signaling pathways play vital roles in human PPGL cell growth. AKT, ERK, and mTOR are activated in most PPGLs. In view of the cross talk between PI3K/AKT/mTOR and MAPK/ERK signaling pathways, we are led to believe that inhibition of multiple pathways may be a novel therapeutic approach for the treatment of PPGLs.

**Ethical Approval**

The study was approved by the PUMCH Ethics Committee for Human Research with an IRB approval number of S-K084.

**Consent**

Informed consent was obtained from all subjects.

**Competing Interests**

The authors of the manuscript have no competing interests to declare.

**Acknowledgments**

The authors are indebted to Dr. Zhengpei Zeng and Dr. Hanzhong Li for providing expert advice. The study is sponsored by the National Key Program of Clinical Science of China (no. WBZY2011-873) and the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry.

**References**

[1] J. W. M. Lenders, G. Eisenhofer, M. Mannelli, and K. Pacak, “Pheochromocytoma,” *The Lancet*, vol. 366, no. 9486, pp. 665–675, 2005.

[2] E. Baudin, M. A. Habra, F. Deschamps et al., “Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma,” *European Journal of Endocrinology*, vol. 171, no. 3, pp. R11–R22, 2014.

[3] J. Bryant, J. Farmer, L. J. Kessler, R. R. Townsend, and K. L. Nathanson, “Pheochromocytoma: the expanding genetic differential diagnosis,” *Journal of the National Cancer Institute*, vol. 95, no. 16, pp. 1196–1204, 2003.

[4] B. E. Baysal, J. E. Willett-Brozick, E. C. Lawrence et al., “Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas,” *Journal of Medical Genetics*, vol. 39, no. 3, pp. 178–183, 2002.

[5] H. P. H. Neumann, B. Bausch, S. R. McWhinney et al., “Germline mutations in nonsyndromic pheochromocytoma,” *The New England Journal of Medicine*, vol. 346, no. 19, pp. 1459–1466, 2002.

[6] L. Amar, J. Bertherat, E. Baudin et al., “Genetic testing in pheochromocytoma or functional paraganglioma,” *Journal of Clinical Oncology*, vol. 23, no. 34, pp. 8812–8818, 2005.

[7] M. Castellano, L. Mori, M. Giaccà et al., “Genetic mutation screening in an Italian cohort of nonsyndromic pheochromocytoma/paraganglioma patients,” *Annals of the New York Academy of Sciences*, vol. 1073, pp. 156–165, 2006.

[8] E. Korpershoek, F. H. Van Nederveen, H. Dannenberg et al., “Genetic analyses of apparently sporadic pheochromocytomas: the Rotterdam experience,” *Annals of the New York Academy of Sciences*, vol. 1073, pp. 138–148, 2006.

[9] C. Segoufin-Cariou and M. Billaud, “Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway,” *Journal of Biological Chemistry*, vol. 275, no. 5, pp. 3568–3576, 2000.

[10] J. Favier and A.-P. Gimenez-Roqueplo, “Pheochromocytomas: the (pseudo)-hypoxia hypothesis,” *Best Practice & Research: Clinical Endocrinology & Metabolism*, vol. 24, no. 6, pp. 957–968, 2010.

[11] S. Nölling and A. B. Grossman, “Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies,” *Endocrine Pathology*, vol. 23, no. 1, pp. 21–33, 2012.

[12] D. K. Morrison, “MAP kinase pathways,” *Cold Spring Harbor Perspectives in Biology*, vol. 4, no. 2, 2012.

[13] R. Hraščan, N. Pečina-Slaus, T. N. Martić et al., “Analysis of selected genes in neuroendocrine tumours: insulinomas and pheochromocytomas,” *Journal of Neuroendocrinology*, vol. 20, no. 8, pp. 1015–1022, 2008.

[14] J. Crona, V. A. Delgado, R. Maharjan et al., “Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing,” *Journal of Clinical Endocrinology and Metabolism*, vol. 98, no. 7, pp. E1266–E1271, 2013.

[15] N. Burnichon, L. Vescovo, L. Amar et al., “Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma,” *Human Molecular Genetics*, vol. 20, no. 20, Article ID ddr324, pp. 3974–3985, 2011.

[16] M. Fassnacht, D. Weismann, S. Ebert et al., “AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 90, no. 7, pp. 4366–4370, 2005.

[17] J. T. Adler, D. G. Hottinger, M. Kunnimalaiyaan, and H. Chen, “Inhibition of the PI3K pathway suppresses hormonal secretion and limits growth in pheochromocytoma cells,” *World Journal of Surgery*, vol. 33, no. 11, pp. 2452–2457, 2009.

[18] S. Wullschleger, R. Loewith, and M. N. Hall, “TOR signaling in fibroblast assembly,” *World Journal of Surgery*, vol. 33, no. 11, pp. E1266–E1271, 2013.

[19] D. A. Guertin and D. M. Sabatini, “Defining the role of mTOR in cancer,” *Cancer Cell*, vol. 12, no. 1, pp. 9–22, 2007.

[20] G. Poulaki, P. Bullova, S. Nölling et al., “Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice,” *Endocrinology*, vol. 154, no. 2, pp. 646–655, 2013.

[21] A.-L. Tong, Z.-P. Zeng, H.-Z. Li, D. Yang, L. Lu, and M. Li, “Expression and effect of transforming growth factor-α and tumor necrosis factor-α in human pheochromocytoma,” *Annals of the New York Academy of Sciences*, vol. 1073, pp. 277–283, 2006.

[22] P. R. Somanath, E. S. Kandel, N. Hay, and T. V. Byzova, “Akt1 signaling regulates integrin activation, matrix recognition, and fibronectin assembly,” *Journal of Biological Chemistry*, vol. 282, no. 31, pp. 22964–22976, 2007.
[23] L. Martinova, E. W. Lai, A. G. Elkahloun et al., “Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature,” *Clinical and Experimental Metastasis*, vol. 26, no. 3, pp. 239–250, 2009.

[24] L. A. Velloso, F. Folli, L. Perego, and M. J. A. Saad, “The multi-faceted cross-talk between the insulin and angiotensin II signaling systems,” *Diabetes/Metabolism Research and Reviews*, vol. 22, no. 2, pp. 98–107, 2006.

[25] A. Goc, B. Al-Husein, S. T. Kochuparambil, J. Liu, W. W. D. Heston, and P. R. Somanath, “PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer,” *International Journal of Oncology*, vol. 38, no. 1, pp. 267–277, 2011.

[26] K. Zitzmann, J. V. Rüden, S. Brand et al., “Compensatory activation of Akt in response to mTOR and Raf inhibitors—a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease,” *Cancer Letters*, vol. 295, no. 1, pp. 100–109, 2010.

[27] K. P. Hoeftcich, C. O’Brien, Z. Boyd et al., “In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models,” *Clinical Cancer Research*, vol. 15, no. 14, pp. 4649–4664, 2009.

[28] C. W. Kinkade, M. Castillo-Martin, A. Puzio-Kuter et al., “Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model,” *Journal of Clinical Investigation*, vol. 118, no. 9, pp. 3051–3064, 2008.

[29] S. Nöltting, E. García, G. Alusi et al., “Combined blockade of signalling pathways shows marked anti-tumour potential in pheochromocytoma cell lines,” *Journal of Molecular Endocrinology*, vol. 49, no. 2, pp. 79–96, 2012.

[30] M. Cargnello, J. Tcherkezian, and P. P. Roux, “The expanding role of mTOR in cancer cell growth and proliferation,” *Mutagenesis*, vol. 30, no. 2, pp. 169–176, 2015.

[31] C. A. Sparks and D. A. Guertin, “Targeting mTOR complex 2 inhibitors in cancer therapy,” *Oncogene*, vol. 29, no. 26, pp. 3733–3744, 2010.

[32] X. Zhang, “The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model,” *Urology*, vol. 85, no. 1, pp. 273.e1–273.e7, 2015.

[33] X. Zhang, X. Wang, T. Xu, S. Zhong, and Z. Shen, “Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma,” *Tumor Biology*, vol. 36, no. 7, pp. 5273–5281, 2015.

[34] L. Q. M. Chow and S. G. Eckhardt, “Sunitinib: from rational design to clinical efficacy,” *Journal of Clinical Oncology*, vol. 25, no. 7, pp. 884–896, 2007.

[35] A. M. Joshua, S. Ezvat, S. L. Asa et al., “Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/ pheochromocytoma,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 94, no. 1, pp. 5–9, 2009.

[36] S. Favier, S. Djelloul, and E. Raymond, “New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors,” *Seminars in Oncology*, vol. 33, no. 4, pp. 407–420, 2006.

[37] Y. Saito, Y. Tanaka, Y. Aita et al., “Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGF-R2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAX,” *American Journal of Physiology-Endocrinology and Metabolism*, vol. 302, no. 6, pp. E615–E625, 2012.

[38] M. Denorme, L. Yon, C. Roux et al., “Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model,” *Cancer Letters*, vol. 352, no. 2, pp. 236–244, 2014.

[39] T. Ikeda, K.-A. Ishii, Y. Saito et al., “Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells,” *Journal of Pharmacological Sciences*, vol. 121, no. 1, pp. 67–73, 2013.

[40] J. Hata, N. Haga, K. Ishibashi et al., “Sunitinib for refractory malignant pheochromocytoma: two case reports,” *International Urology and Nephrology*, vol. 46, no. 7, pp. 1309–1312, 2014.

[41] M. Ayala-Ramirez, C. N. Chougnnet, M. A. Habra et al., “Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 97, no. 11, pp. 4040–4050, 2012.

[42] F. M. Brouwers, A. G. Elkahloun, P. J. Munson et al., “Gene expression profiling of benign and malignant pheochromocytoma,” *Annals of the New York Academy of Sciences*, vol. 1073, pp. 541–556, 2006.